Neoadjuvant Tislelizumab Combined With Albumin-paclitaxel, Cisplatin, and Fluorouracil in Patients With Locally Advanced Oral Squamous Cell Carcinoma A Single-arm, Prospective Phase II Study
Latest Information Update: 07 Jan 2025
At a glance
- Drugs Cisplatin (Primary) ; Fluorouracil (Primary) ; Paclitaxel (Primary) ; Tislelizumab (Primary)
- Indications Carcinoma; Mouth neoplasm; Squamous cell cancer
- Focus Therapeutic Use
- 14 Jul 2023 Status changed from not yet recruiting to recruiting.
- 19 May 2023 New trial record